Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference
Authors:
- Manuela RabaglioMRManuela Rabaglio
- Stefan AebiSAStefan Aebi
- Monica Castiglione-GertschMCMonica Castiglione-Gertsch
- 1 October 2007
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 8 (10) , 940-949
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Similar Efficacy for Ovarian Ablation Compared With Cyclophosphamide, Methotrexate, and Fluorouracil: From a Randomized Comparison of Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast CancerJournal of Clinical Oncology, 2006
- CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: A randomised trial (GABG trial IV-A-93)European Journal of Cancer, 2006
- Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trialAnnals of Oncology, 2006
- Adjuvant Chemotherapy Followed by Goserelin Versus Either Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer: A Randomized TrialJNCI: Journal of the National Cancer Institute, 2003
- Survival analyses from the ZEBRA studyEuropean Journal of Cancer, 2003
- Italian Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group Trials1998
- Therapy in Premenopausal Women with Advanced, Oestrogen Positive or/and Progesterone Positive Breast Cancer: Surgical Oophorectomy versus the LHRH Analogue, ZoladexHormone Research, 1989
- Prophylactic oophorectomy in breast cancer therapyThe American Journal of Surgery, 1969
- AN OVARIAN HORMONEJAMA, 1923
- ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1The Lancet, 1896